Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Disease caused by the Chlamydophila psittaci bacteria, usually transmitted from birds to humans.
Biomarker and diagnostic research for ornithosis has been reported in the published literature.
1 FDA-approved treatment is available for ornithosis, including MINOCYCLINE HYDROCHLORIDE (MINOCIN, approved 1972).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
2 clinical trials registered. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE3, 1 NA. Research is primarily sponsored by academic and government institutions.
121 publications have been identified in PubMed for ornithosis. Research spans Case Report / Case Series (35%), Epidemiology / Natural History (21%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 42 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:47 AM UTC
European rare disease database
MINOCYCLINE HYDROCHLORIDE |
— |
1972 |
Available |
Gene therapy approaches for ornithosis have been reported in the published literature.
2 trials found
Disease patterns and progression | 26 | 21% |
Research summaries | 17 | 14% |
Clinical study results | 14 | 12% |
Laboratory research | 10 | 8% |
Testing and diagnosis research | 6 | 5% |
Other research | 3 | 2% |
New treatment approaches | 3 | 2% |
Song Y (2026). [PMID: 41878259](https://pubmed.ncbi.nlm.nih.gov/41878259/). *Front Cell Infect Microbiol*. [Diagnostic / Biomarker]
Xu L (2026). [PMID: 41708036](https://pubmed.ncbi.nlm.nih.gov/41708036/). *Int J Biol Macromol*. [Gene Therapy / Novel Therapeutics]
Fang C (2026). [PMID: 41859052](https://pubmed.ncbi.nlm.nih.gov/41859052/). *Infect Drug Resist*. [Case Report / Case Series]
Yao Y (2026). [PMID: 41678126](https://pubmed.ncbi.nlm.nih.gov/41678126/). *Eur J Clin Microbiol Infect Dis*. [Diagnostic / Biomarker]
Chu J (2026). [PMID: 30855889](https://pubmed.ncbi.nlm.nih.gov/30855889/). *Unknown Journal*. [Epidemiology / Natural History]
Yao W (2026). [PMID: 41853713](https://pubmed.ncbi.nlm.nih.gov/41853713/). *Front Microbiol*. [Epidemiology / Natural History]
Wang B (2026). [PMID: 41702480](https://pubmed.ncbi.nlm.nih.gov/41702480/). *Infect Genet Evol*. [Review / Meta-Analysis]
Shu Q (2026). [PMID: 42159113](https://pubmed.ncbi.nlm.nih.gov/42159113/). *Clin Lab*. [Case Report / Case Series]
Barnekow T (2026). [PMID: 41776660](https://pubmed.ncbi.nlm.nih.gov/41776660/). *J Occup Med Toxicol*. [Epidemiology / Natural History]
Yan X (2026). [PMID: 41579410](https://pubmed.ncbi.nlm.nih.gov/41579410/). *Immunobiology*. [Basic Science / Preclinical]